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Abstract The pancreatic beta cell is responsible for main-
taining normoglycaemia by secreting an appropriate amount
of insulin according to blood glucose levels. The accurate
sensing of the beta cell extracellular environment is there-
fore crucial to this endocrine function and is transmitted via
its cell surface proteome. Various surface proteins that me-
diate or affect beta cell endocrine function have been iden-
tified, including growth factor and cytokine receptors,
transporters, ion channels and proteases, attributing impor-
tant roles to surface proteins in the adaptive behaviour of
beta cells in response to acute and chronic environmental
changes. However, the largely unknown composition of the
beta cell surface proteome is likely to harbour yet more
information about these mechanisms and provide novel
points of therapeutic intervention and diagnostic tools. This
article will provide an overview of the functional complex-
ity of the beta cell surface proteome and selected surface
proteins, outline the mechanisms by which their activity
may be modulated, discuss the methods and challenges of
comprehensively mapping and studying the beta cell surface
proteome, and address the potential of this interesting
subproteome for diagnostic and therapeutic applications in
human disease.
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Abbreviations
ADAM A disintegrin and metalloproteinase
BACE2 Beta-site amyloid precursor protein cleaving
enzyme 2
CAM Cell adhesion molecule
ECM Extracellular matrix
EGFR Epidermal growth factor receptor
GO Gene Ontology
GLP-1 Glucagon-like peptide 1
GSIS Glucose-stimulated insulin secretion
IAPP Islet amyloid polypeptide
PTM Post-translational modification
PTPRN Receptor-type tyrosine-protein
phosphatase-like N
Introduction
The endocrine part of the pancreas is composed of the islets
of Langerhans, which are highly vascularised and innervated
‘mini-organs’ accounting for 1–2% of the total pancreatic
mass. An islet consists of 50–80% of insulin-secreting beta
cells [1], which are clustered with four other endocrine cell
types: the glucagon-secreting alpha cells, somatostatin-
secreting delta cells, pancreatic polypeptide-secreting cells
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of the beta cell is to respond to increases in blood glucose
levels by secreting insulin, which triggers the uptake of
glucose from the blood in insulin-sensitive tissues, where
glucose is used as a fuel for ATP generation or converted
into energy-storing macromolecules. Additionally, insulin
acts as a growth hormone and induces satiety signalling in
the brain, again, indicating glucose availability. Transiently,
beta cells respond to elevated glucose levels by increasing
insulin secretion (and workload) per cell. Chronically aug-
mented insulin demands, such as during pregnancy, child
growth and insulin resistance in obesity, are responded to
not only by increased insulin secretion, but also by beta cell
proliferation, so that the net insulin secretory capacity is
raised, the individual workload is reduced and the beta cells
are protected from glucotoxicity [2]. These adaptive pro-
cesses are collectively termed ‘beta cell compensation’ [3]
and, in addition to raised blood glucose levels, require the
communication of pancreatic beta cells with other tissues
(via circulating factors) and neighbouring cells that may be
endocrine or non-endocrine, e.g. of vascular, neuronal or
haematopoietic origin [4].
In line with this notion, various surface proteins that are
critical for beta cell function, in that they participate in many
pivotal steps of glucose-stimulated insulin secretion (GSIS)
and are essential for proliferation, islet integrity and differ-
entiation, have been identified. With the increasing preva-
lence of diabetes [5], focused attention has also been given
to the mechanisms that lead to beta cell dysfunction and
deficits in beta cell mass in type 1 and type 2 diabetes.
However, the list of well-characterised beta cell surface
proteins is short and composed of individual members that
have been studied in different laboratories in the context of
the respective research focus. Thus, the systematic mapping
and characterisation of the beta cell surface proteome may
be crucial for better understanding beta cell physiology in
health and disease-related abnormalities. Furthermore, from
a practical point of view, surface proteins are potentially
more accessible than intracellular targets and are therefore
particularly interesting targets for the development of diag-
nostic and therapeutic strategies.
The beta cell surface proteome inventory
The beta cell surface proteome is defined by the entire set of
beta cell proteins that are either embedded in, or extracellu-
larly associated with, the plasma membrane. Given that the
beta cell is a secretory cell, the secretome, which is the
collective set of proteins that is released by a cell through
classical (signal peptide-dependent) and unconventional or
exosomal pathways [6], is part of the surface proteome as
well. Some proteins pass through the plasma membrane
only during the exocytotic process, while others integrate
through vesicle docking/fusion or associate with cell surface
receptors after secretion. Another subset of the proteome is
the sheddome, comprising the cell surface protein extracel-
lular cleavage products that arise from proteolytic process-
ing at the plasma membrane. Together with the secretome,
the sheddome is potentially a clinically relevant source of
biomarkers and therapeutic target discoveries, which will be
described later.
The total number and relative abundance of beta cell
surface proteins is currently unknown, but computational
prediction tools combined with transcriptomic and proteo-
mic approaches can tell us what the beta cell surface may
look like (Fig. 1). In a recent bioinformatics approach, a
total of 3,702 transmembrane proteins were predicted, ac-
counting for ∼15–20% of all human genes [7] (similar
percentages are anticipated for the human secretome [8]).
Searching for these proteins in the Beta Cell Gene Atlas
[9]—a collection of publically available microarray data
generated from the analysis of pancreatic beta cells and
related cell types—reveals that, of these, 1,212 genes are
expressed in primary human beta cells, while 353 are not
(no data are available for the remainder; see Electronic
supplementary material [ESM] Table 1). A recent proteomic
study aimed at the identification of N-linked glycoproteins
identified nearly 1,000 glycoproteins of mouse beta cells
and human islets (available online via the dBETA database,
http://biodata.ethz.ch/cgi-bin/beta.py), of which 349 pro-
teins were found at the cell surface in the murine beta cell
line MIN6 [10]. Of these, 172 proteins are also found in
human islets, thus representing potential human beta cell
surface proteins [10]. With further progress and refinements
in mass spectrometry-based technologies, hypothetical beta
cell surface candidate proteins (i.e. bioinformatically pre-
dicted surface proteins expressed in beta cells according to
transcriptomic data) as well as possibly unanticipated sur-
face proteins (which are, owing to the lack of a signal
peptide, not predicted but may localise to the cell surface
via unconventional pathways [11]) are likely to be validated
or identified. In addition, it is likely that the beta cell surface
displays proteins that are also produced in other, non-
endocrine tissues, although possibly at different levels.
However the beta cell plasma membrane proteome may be
defined by beta cell-enriched macromolecules that are
shared primarily with other neuroendocrine cell types or
that are really beta cell specific. Several studies have indeed
identified islet and beta cell enriched surface proteins
[12–16]. Hence, comparisons of cell surface proteins be-
tween different cell types reveal specificity as well as the
selective absence of proteins in beta cells. In fact, the con-
cept of beta cell specific depletion of cell surface proteins
has already emerged [17], which can contribute to the un-
derstanding of beta cell physiology as well. For example,
1878 Diabetologia (2012) 55:1877–1889expression of platelet-derived growth factor receptor
declines over the course of a lifetime, which correlates with
the age-dependent loss of beta cell proliferative capacity
[18]; the lack of monocarboxylate transporter-1 explains
the pyruvate paradox (i.e. the failure of pyruvate and lactate
to stimulate insulin secretion), which, in turn, avoids inap-
propriate insulin release during physical exercise [19].
The so far functionally studied surface proteome of
pancreatic beta cells is composed of a structurally diverse
network of proteins that interacts with environmental mole-
cules, including metabolites, ions, hormones, various pep-
tides and proteins (Fig. 2). According to Gene Ontology
(GO) analysis the majority of its members fall into the
categories of proteins with receptor, transporter, calcium
ion binding, peptidase, kinase, G-protein coupled receptor
and ion channel activity [10]. Most of them have also been
linked to one of the three most important aspects in the life
of a healthy beta cell, namely differentiation, survival/pro-
liferation and insulin secretion. The function of some ‘clas-
sical’ beta cell surface receptors and their downstream
signalling pathways, depicted in Fig. 2, have been exten-
sively covered elsewhere [20–22], but in the context of
mapping the beta cell surface proteome, special attention
should also be paid to the proteins mediating cell–cell con-
tacts: when working with primary islets and isolated beta
cells their activity will have to be interrupted in most cases,
and yet they are pivotal for beta cell function.
The concept that beta cells cannot operate properly auto-
nomically but rather require intercellular contacts with other
beta cells and surrounding endocrine and non-endocrine
cells is underscored by early observations that isolated beta
cells secrete less insulin in response to glucose compared
with intact islets and that reaggregation of islet cells can
partially restore these deficits [23, 24]. Similarly, islets and
purified beta cells exhibit a better survival rate and secrete
more insulin in response to glucose when plated on extra-
cellular matrix (ECM) components rather than on standard
culture-treated plastic dishes [25, 26]. The major proteins
that mediate cell–cell interactions and contacts with the
ECM are cell adhesion molecules (CAMs) such as cadher-
ins, immunoglobulin CAMs, and integrins, and defects in
beta cell function have been observed when there is a lack of
proteins from each of these classes. For example, E-cadherin
deficiency prevents the formation of MIN6 pseudoislets, i.e.
spherical cell clusters that show improved stimulated insulin
secretion compared with monolayers [27], while overex-
pression of the gene for E-cadherin (Cdh1) is linked to the
limited proliferation rate of these assemblies [28]. Further-
more, a transgenic mouse model producing a dominant-
negative form of E-cadherin that displaces wild-type E-
cadherin and N-cadherin on the beta cell surface shows
defects in the clustering of beta cells with other endocrine
cells into islets during pancreatic development [29]. Like-
wise, a Ca
2+-independent CAM of the immunoglobulin
superfamily, neural cell adhesion molecule (N-CAM), is
implicated in pancreatic islet morphogenesis [30, 31], and
N-CAM-deficient mice exhibit impaired segregation of cells
during organogenesis of pancreatic islets [30], and the adult
mice have hyperinsulinaemia and impaired glucose toler-
ance because of enhanced basal insulin secretion and
impaired insulin release at high glucose concentrations,
respectively [32]. Integrin receptors, heterodimers of an α-
Fig. 1 Chart of cell surface proteins predicted to be expressed in
human beta cells. At 15–20 %, the predicted human surface membrane
proteome constitutes a large part of the whole proteome [7, 8, 100].
Predicted cell surface proteins (blue) [7], anticipated cell surface pro-
teins as determined by mRNA expression in human beta cells by the
Beta Cell Gene Atlas (green) [9] and high-confidence human beta cell
surface proteins as determined by N-linked glycoprotein cell surface
proteomics (red) [10]. Note that for a large proportion of the predicted
cell surface proteins no gene expression data are available. The secre-
tome and sheddome were not considered in this graph because of a lack
of comprehensive proteomic data
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non-islet cells (e.g. endothelial cells) and are also required
for beta cell function. The ligand binding and activation of
integrin receptors enables contact to a microenvironment
formed by endothelial cells, a vascular niche, which
supplies beta cells with a vascular basement membrane that
stimulates endocrine function and permits beta cell prolifer-
ation [33, 34]. Another type of cell-to-cell contact that
enables the direct exchange of cytoplasmic ions, metabolites
and other small signalling molecules is established by gap
junction channels. These intercellular membrane channels
are formed by two connexons, which are tubular structures
of six connexins joining end-to-end over the extracellular
space. Rodent and human beta cell gap junctions are formed
by connexin-36 [35, 36], which coordinates calcium sig-
nalling and synchronisation of beta cells. Decreases in
connexin-36 levels lead to defects in basal and glucose-
stimulated insulin secretion [37, 38]. Beta-to-beta cell con-
tact also enables bidirectional signalling, which is mediated
by EphA receptor tyrosine kinases and ephrin-A ligands
[39]. Under low glucose conditions, forward signalling by
EphA inhibits insulin secretion, whereas under high glucose
Fig. 2 Selected beta cell surface proteins implicated in important
functional aspects of the beta cell. Binding of insulin to the insulin
receptor (IR) and insulin-like growth factor receptor (IGF-1R), as well
as EGFR signalling, activates downstream effector molecules that
positively regulate beta cell function and proliferation. In insulin
granule exocytosis glucose is transported across the beta cell
membrane via the glucose transporters GLUT2 and GLUT1 in humans.
The metabolism of glucose results in a rise in the ATP/ADP ratio,
which promotes ATP-sensitive potassium channel (KATP channel)
closure, membrane depolarization, and opening of voltage-gated
calcium channels. The increasing intracellular Ca
2+ concentrations
trigger the exocytosis of insulin granules. Insulin secretion is also
influenced by fatty acids through G-protein coupled receptor
(GPR40) signalling by the mobilisation of endoplasmic reticulum
(ER) calcium stores and signalling through protein kinase C (PKC).
GLP-1 receptor stimulates glucose induced insulin secretion by
increasing cyclic adenosine 3′,5′-monophosphate (cAMP) levels and
activation of protein kinase A (PKA) and guanine nucleotide exchange
factor EPAC2. PKA and PKC can lead to phosphorylation of multiple
proteins involved in the regulation of insulin secretion. In contrast,
alpha adrenergic receptors inactivate adenyl cyclase (AC) and the
formation of ATP, thus inhibiting insulin release. The solid lines
indicate direct, immediate reactions. Note: The figure does not contain
details of all the downstream signalling pathways of the depicted beta
cell surface proteins. For further explanations, see text. DAG, diacyl-
glycerol; IL-1R, interleukin-1 receptor; IRS, insulin receptor substrate;
IP3, inositol 1,4,5-trisphosphate; MEK/ERK, mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase; MHC, major histo-
compatibility complex; PIP2, phosphatidylinositol 4,5-bisphosphate;
PI3K, phosphatidylinositol 3-kinase; PLC, phospholipase C
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enhances insulin secretion [39]. Finally, neuronal parasym-
pathetic innervations of islets can, for example, activate
muscarinic acetylcholine receptors such as M3 in beta cells
to promote GSIS [40]. In contrast, sympathetic innervation,
e.g. signalling through α2-adrenoreceptors inhibits insulin
secretion [41]. Another layer of complexity is added by the
fact that beta cells within the islet, and islets themselves, are
morphologically and functionally heterogeneous [42],
which is also reflected in differential cell surface profiles
and dynamics. For example, beta cell surface levels of
CAMs differ from one cell to another, and their abundance
correlates with the functional activity of beta cells in vitro
[26, 43, 44].
While a plethora of information on the beta cell surface
proteome is thus available, there are three major deficits in
our current view. First, its dynamic nature tends to be under-
studied. The qualitative and quantitative composition of any
surface proteome will vary according to the extracellular
and intracellular environment, which may, for example,
reflect an organism’s developmental stage or nutritional
status, or could be influenced by specific pathologies.
Second, there is no high-coverage dataset available that
identifies the surface proteins that are dysregulated and
are involved in type 1 and type 2 diabetes. Third, its
global coverage (i.e. the identification/validation of pro-
teins on the beta cell plasma membrane) is still poor
(see Fig. 1). These three aspects will be discussed in the
following sections.
The majority of the beta cell surface proteins studied to
date have been linked to one of the three most important
aspects in the life of a healthy beta cell: differentiation,
survival/proliferation and insulin secretion
Beta cell surface dynamics—transcription, traffic,
turnover
Although some proteins are permanently expressed at the
cell surface, the beta cell surface proteome is highly dynam-
ic, with many factors being only temporarily exposed at the
plasma membrane. In a constantly changing environment,
the surface profile of a cell needs to be able to adapt
appropriately. There are several mechanisms by which a cell
may achieve this, and they include altered transcription,
translation, protein trafficking, post-translational modifica-
tions (PTMs) and, in particular, selective and limited cleavage
at the plasma membrane, which controls the fate and activity
of various cell surface proteins. There may be a decision
hierarchy to these processes, whereby gene expression tends
tobethemostlong-termandlong-lastingresponse,trafficking
a faster adapting modulator, and certain PTMs the most acute
reactions to change. Various plasma membrane proteins are
subject to most of these pathways, which may act synergisti-
cally to ensure the tight regulation of surface expression.
Modulations in gene transcription in response to environ-
mental changes have been observed for various beta cell
surface proteins, one example being the expression of the
prolactin receptor (Prlr)[ 45] and 5-hydroxytryptamine (se-
rotonin) receptors 1D and 2B (Htr1d and Htr2b)[ 46]. Some
high-coverage data on beta cell surface dynamics at the
transcriptional level are probably hidden in various
transcriptome-wide studies, but are subject to two pitfalls:
(1) they only account for relatively long-term proteome
changes, and (2) they do not always correlate with protein
levels at the cell surface. Hence, they may not actually
describe what the cell surface looks like, as the abundance
of proteins in a cell is not necessarily uniform and local-
isation might be concentrated in specific, possibly non-
plasma membrane compartments under a certain condition.
The transport of proteins to and from the plasma mem-
brane is guided via vesicular trafficking between compart-
ments of the secretory and endocytic pathways. Non-
conventional secretory pathways have been described [11,
47] that may also contribute to the exposure of proteins on
the beta cell surface. In the beta cell the insulin granule,
which partially fuses with the plasma membrane during
GSIS, is an additional source of proteins transiently exposed
on the plasma membrane and so transmembrane proteins
such as receptor-type tyrosine-protein phosphatase-like N
(PTPRN), which are resident in insulin granules, are also
found on the cell surface [48]. Over the years it has been
shown that beta cells are polarised and that this asymmetry
is reflected by the uneven distribution of surface proteins,
such that the major glucose transporter, GLUT2, is enriched
in lateral microvilli [49] or TMEM27, a mitogenic type1
transmembrane protein, is enriched in primary cilia [50].
Furthermore, specific surface proteins segregate in
cholesterol-rich microdomains known as lipid rafts, such
as the major beta cell voltage gated Ca
2+ channel CaV1.2
and the voltage-gated K
+ channel KV2.1 [51]. Since these
domains have been implicated in concentrating signal trans-
duction modules and affecting important cellular functions
such as GSIS [51–53], this selective targeting will also alter
the function of the surfaceome. Again, however, compre-
hensive information on beta cell trafficking pathways and
their cargo under specific conditions is currently lacking,
not least because its acquisition requires challenging exper-
imental set-ups and technologies that have only recently
become available.
PTMs of surface proteins, including glycosylation, lipi-
dation, sialylation, phosphorylation, sumoylation and acet-
ylation, may also act as stabilising or destabilising signals.
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stability and proper localisation [54], and phosphorylation
of epidermal growth factor receptor (EGFR) triggers its
removal from the plasma membrane by endocytosis, a pro-
cess known as receptor downregulation [55]. One particular
form of PTM elicits turnover of cell surface proteins by
proteolytic processing, which is of special interest for the
following reasons: (1) as opposed to most other PTMs it is
irreversible and thus a ‘stronger’ cellular decision; (2) it
takes place at the plasma membrane itself, which exposes
the process directly to the environment the cell needs to
adapt to and makes it ideally poised for an imminent reac-
tion; (3) given its cell surface location, it is potentially
therapeutically accessible; and (4) the cleavage products
may have biological functions on their own or, in theory,
can be exploited as a readout for a particular cellular
function(s). Ectodomain cleavage, or shedding, of membrane
proteins is carried out by cell surface proteases, and this
substrate-specific cleavage not only influences full-length
protein activity, transport and turnover, but also generates a
soluble and sometimes bioactive molecule. In fact, some shed
fragments have been described to be functional soluble
receptors or ligands, which participate in autocrine, juxtacrine
and paracrine signalling, or act as decoy receptors that
sequester ligands to permit permanent signalling [56].
They are evidently also potential biomarkers of beta cell
function and mass (see later). In addition, the initial cleavage
step by a sheddase also generates a membrane-bound
fragment of a surface protein substrate, which is frequently
subject to a further processing step termed regulated
intramembrane proteolysis [56–58], which is thought to
take place mainly in an intracellular compartment. The
liberated intracellular cytosolic fragments may enter the
nucleus to control gene transcription [56].
In recent years a growing number of transmembrane
proteins of various topologies have been identified that are
cleaved in the plane of the cellular membrane and, because
of their diversity, they have been implicated in a number of
different cellular processes, including cell signalling, cell
adhesion, protein localisation, and pathological conditions
such as cancer. On the flip side of the coin, several proteases
have now been discovered, and the identification and func-
tional characterisation of their substrate will likely deter-
mine which are the best candidates to be targeted by
protease inhibitors. Of the roughly 650 proteases encoded
in the murine genome [59, 60], about 130 predicted trans-
membrane or ECM-associated proteins are thought to be
expressed in murine islets or beta cell lines (based on Affy-
metrix gene expression analysis). Of these, 29 have recently
been confirmed to be expressed either by cell surface mass
spectrometry or real-time PCR [15]. These include the clas-
sical sheddases, such as beta-site amyloid precursor protein
cleaving enzymes 1 and 2 [BACE1 and BACE2] of the
aspartyl protease family and members of the ‘a disintegrin
and metalloproteinase’ (ADAM) family, as well as other
proteases. Examples of beta cell-enriched cell surface pro-
tease–substrate pairs that regulate function and mass include
ADAM10 and its substrate epidermal growth factor (EGF)
that becomes a soluble ligand for EGFR and thus induces
proliferation [61], the sheddase BACE2 and its target
TMEM27, which is inactivated by cleavage [30], and the
protease calpain 1, which cleaves PTPRN to produce an
intracellular fragment that can enter the nucleus to stabilise
active STAT5. Cleaved PTPRN thereby increases transcrip-
tion of secretory granule genes and stimulates beta cell
proliferation [62, 63]. However, this information is only a
starting point for the study of the protease-specific shed-
dome and the regulation of the surface proteases themselves
under different physiological and pathological conditions in
beta cells.
Many plasma membrane proteins are subject to regulation
by transcription, PTMs, trafficking and turnover—processes
that act synergistically to ensure the tight regulation of
plasma membrane protein levels
The beta cell surface proteome in type 1 and type 2
diabetes
In the context of diabetes, there are two categories of beta
cell surface proteins of interest: those that are causally
involved in disease development and those that can be used
for diagnostic and treatment purposes (of course, some
proteins may fall into both classes). In healthy individuals
the beta cell senses its environment and adjusts its function
and mass to meet metabolic needs, ensuring that plasma
glucose concentrations remain within a relatively narrow
physiological range. Thus, insulin release by human beta
cells can be increased by about four- to fivefold and beta cell
mass enhanced by about 50% during insulin resistance [64,
65]. The beta cell surface proteins that contribute to type 1
diabetes are likely to be very different from those involved
in type 2 diabetes. The fundamental pathology of type 1
diabetes is autoimmune-mediated beta cell destruction,
which results in an absolute deficiency of insulin, with only
about 1% of beta cell mass remaining in individuals with
lifelong type 1 diabetes at autopsy [66, 67]. In contrast, type
2 diabetes is characterised by beta cell dysfunction that is
thought to occur very early in the disease, even preceding
insulin resistance [66, 68], and only later by reduced beta
cell mass (a loss of up to 63% in long-term type 2 diabetes)
[64]. Evidently, the systematic analysis of the changes in the
beta cell surface proteome, sheddome and secretome in
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is urgently required to gain a more comprehensive and
molecular understanding of disease development and novel
treatments.
Several type 1 diabetes susceptibility genes have been
identified, with particular correlations found for histocom-
patibility antigens. HLA class I and class II genes present
antigens to antigen-specific receptors that mediate antigen
recognition by immune effectors. The chronic autoimmune
reaction in type 1 diabetes is directed towards specific beta
cell antigens, which include the beta cell surface proteins
insulin, PTPRN (which is also known as insulinoma antigen
2 or IA-2) and zinc transporter 8 (also referred to as ZNT8
or SLC30A8) [69]. The presence of autoantibodies against
these proteins is used for diagnostic purposes. Additionally,
severe beta cell impairment and loss can be triggered by
viruses that use beta cell surface proteins as receptors, e.g.
the cell adhesion protein coxsackie virus and adenovirus
receptor (CXADR) or Toll-like receptors. Indeed, virus
genomes have been sequenced from samples obtained at
the autopsy of individuals with type 1 diabetes [70] and
virus-neutralising antibodies can be serologically detected in
many type 1 diabetic patients [71], giving rise to the notion
thatbetacellsurface protein-mediatedviral infection can even
be the triggering event for the disease. The viral infection may
be cytotoxic on its own and/or cause the beta cell to increase
its cellsurface levelsofthe major histocompatibilitycomplex,
whichpresentsbetacellproteinstoTcells,andinducethebeta
cell secretome of inflammatory cytokines such as IFNα and
IFNβ, which will also elicit an adaptive immune response
(reviewed in detail elsewhere [72]).
Inflammation induced by the release of beta cell cyto-
kines also plays a role in type 2 diabetes, but in this case it
arises from endoplasmic reticulum stress caused by exces-
sive nutrient uptake (collectively called glucotoxicity and
lipotoxicity) and insulin production. Since the beta cell
glucose transporter GLUT2 (and GLUT1 in humans) is
constitutively expressed so that the cell can accurately sense
blood glucose levels, beta cells may be particularly vulner-
able to glucotoxicity. On the other hand, decreased islet
GLUT2 levels have been found in a mouse model of muscle
insulin resistance, along with reduced critical insulin gran-
ule surface proteins such as vesicle-associated membrane
protein 2 (VAMP2) [73], suggesting that a vicious cycle of
impaired glucose sensing and insulin secretion ensues over
time. Another example of a cell surface protein that has even
genetically been linked to type 2 diabetes is the fatty acid
receptor GPR40 [74]. In addition, the beta cell secretome is
altered in individuals with type 2 diabetes, for example, it
displays increased amounts of proinsulin [75] and augment-
ed levels of human islet amyloid polypeptide (IAPP) (which
is co-secreted with insulin). Human IAPP, islet amyloid
deposits of which are found in type 2 diabetes, aggregates in
the ECM and induces apoptosis and defects in insulin secre-
tion [76].
While the therapeutic potential of the beta cell surface
will be discussed in detail later on, it is worth pointing out at
this stage that many of the best-established treatments for
diabetes simulate or boost the action of this subproteome.
Insulin substitution is the only treatment available for type 1
diabetes at the moment. However, the hyperglycaemia in
type 2 diabetes can be alleviated by sulfonylureas such as
glibenclamide that bind and block the sulfonylurea receptor
1 (SUR1) subunits of the inwardly rectifying ATP-sensitive
potassium channel (KATP channel), closure of which is
essential for membrane depolarisation that initiates insulin
secretion [77]. Dipeptidyl peptidase IV (DPPIV)-resistant
glucagon-like peptide 1 (GLP-1) analogues (e.g. exenatide)
or DPPIV inhibitors (e.g. sitagliptin) are used to potentiate
GSIS and promote beta cell proliferation via increased
GLP-1 receptor activity [20]. The relative success of the
glucose-lowering strategies targeting the beta cell surface
proteome highlight the importance of this subproteome in
the disease.
The relative success of glucose-lowering strategies targeting
the beta cell surface proteome in type 2 diabetes highlight
the importance of this subproteome in the disease
Approaches to map and characterise the beta cell
surface proteome
Clearly, the expansion of qualitative as well as quantitative,
dynamic coverage of the pancreatic beta cell surface pro-
teome will increase our understanding of this cell type. The
logical approach is to (1) establish the plasma membrane
proteins of a certain cell type under given conditions (find-
ing the beta cell ‘bar code’); (2) distinguish between those
crucial for the cell’s function and the dispensable/redundant
ones, which is relevant for the identification of new thera-
peutic targets; and (3) selecting those that are somewhat cell
specific and therefore confer target tissue selectivity. Mass
spectrometry-based methods are the method of choice for
the identification and quantification of proteins in complex
protein samples [78]. While quantitative, dynamic proteome
mapping is always challenging, this is particularly true in
the case of the pancreatic beta cell surface proteome. Pri-
mary beta cells are harder to acquire than many other cell
types (see below), and transmembrane proteins are the most
challenging group of proteins to analyse as a result of the
heterogenic and amphipathic nature of membrane proteins,
combined with their limited abundance compared with cy-
tosolic proteins. Thus, the largest determined (mouse) islet
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teins, about a third of which are categorised as membrane
and extracellular proteins by GO analysis [79]. The limita-
tions in the identification of surface proteins have been
addressed, in part, by protocols that involve the enrichment
and separation of membrane proteins from cytosolic proteins
through subcellular fractionation or chemical labelling fol-
lowed by mass spectrometric analysis [80]. Current methods
encompass enriching centrifugation and extraction techniques
[81],coatingofplasmamembranesusingsilicabeads[82,83],
affinity-based approaches (e.g. lectin- and antibody-based
protocols) [84–86], cell surface ‘shaving’ [87]o fi n t a c tc e l l s
with proteases, and methods that chemically tag surface pro-
teins such as biotinylation [88] and glycoprotein capturing
[89–92]. A mixture of different approaches will ultimately
providehighercoverageofthesurfaceproteome,asillustrated
by a recent study on human pancreatic islets in which a
combination of different extraction techniques increased the
total to 343 identified membrane proteins [93].
Chemical tagging strategies have been a popular choice
for enrichment because labelled surface proteins can subse-
quently be resolved from unlabelled proteins by affinity
purification, an advantage over classical ultracentrifugation
preparations that are typically contaminated by proteins
from intracellular membranes [80]. Plasma membrane bio-
tinylation protocols involve the covalent labelling of extra-
cellular proteins with a biotinylation reagent [94], followed
by capture of the biotin-conjugated proteins or peptides via
an avidin-/streptavidin-coated solid support. The bound pro-
teins/peptides are eluted from the affinity matrix and ana-
lysed by mass spectrometry. Glycoprotein capturing is based
on solid-phase extraction of N-linked glycopeptides, and
has been successfully used to identify and quantify N-
linked glycoproteins from serum and cellular samples [89,
91]. This method has been further developed by cell surface
capturing (CSC), in which extracellular glycan moieties of
intact, living cells are chemically labelled [90, 92]. Glycans
on the surface of intact cells are oxidised and the formed
aldehydegroupsarecoupledtoabi-functionallinkermolecule
(biocytin hydrazide). After cell homogenisation, a crude
membrane fraction is isolated by ultracentrifugation and pro-
teins are extracted and digested. The labelled peptides are
isolated using affinity capture, and the peptides are released
byenzymaticcleavageofthecarbohydratechainandanalysed
by mass spectrometry. Both the whole cell glycocapture ap-
proach and the cell surface-capturing approach have been
successfully used to identify beta cell N-linked glycoproteins,
and quantitative monitoring identified 24 proteins that are up-
or downregulated after stimulation by glucose and GLP-1
[10]. In addition, various strategies that are commonly used
to determine surface protease substrates can also be applied to
pancreaticbetacells.These involve the analysisofcell culture
mediumproteomes and theidentificationofthe N-terminome,
the amino acidsequencethatisgenerated after cleavage ofthe
amide bond by the protease [95]. Finally, protein candidates
canbevalidatedinfollow-upstudies usingtargetedproteomic
approaches such as single reaction monitoring (SRM) assays,
which enable the accurate quantification of selected peptides
in complex samples [96].
The application of any of these proteomic techniques to
primary pancreatic islets, and beta cells in particular, adds an
extra hurdle to the task as, given the organ’s size and the
ethical issues associated with the acquisition of primate
material, the achievable input sample amounts are limited.
The advantage of using primary purified beta cells is that
contaminating proteins from other endocrine cell types,
which bias the result, are removed. However, the disintegra-
tion of the unique islet structure followed by culture and cell
sorting involves many treatments that affect cell viability
and function (see above), which will reduce the functional
integrity of the surface proteome. Therefore, the use of
intact pancreatic islets in combination with insulinoma cell
lines originating from different species and under different
experimental conditions (e.g. high versus low glucose level
media) facilitates the cataloguing of the beta cell surface
proteome. In a complementary approach the surface pro-
teome of beta cell-interacting cells, such as exocrine tissue
and alpha cell lines, can be characterised to identify beta
cell-specific versus contaminating/common proteins.
The development and continuous refinement of surface
protein separation methods over the past years, with an
increasing role of surface labelling techniques, facilitates
the study of surface proteins on a global scale and the
discovery of new beta cell surface markers
Although there is currently no ‘gold standard’ workflow
that would allow the whole spectrum of the beta cell pro-
teome to be covered, monitoring a critical number of beta
cell surface proteins under different experimental perturba-
tions (which should ideally be numerous and diverse) may
be sufficient to unveil patterns of co- or antagonistic regu-
lation, which could indicate common trafficking, localisa-
tion, interaction and function. This will accelerate the
identification of putative therapeutic targets or biomarkers
and at the same time provide a direction for the functional
analysis of individual hits. Another crucial step in this initial
assessment is the verification of whether the emerging can-
didate proteins are also expressed on human beta cell as,
inevitably, the surface proteome may differ, especially quan-
titatively, between humans and other vertebrates. For exam-
ple, it is known that rodent beta cells use GLUT2 for
glucose uptake, while human beta cells express much less
of this transporter and instead also take up glucose via
GLUT1 [97]. Differences between humans and mice also
1884 Diabetologia (2012) 55:1877–1889exist in the expression of potential surface proteases [59]
and, consequently, in substrate processing. The relevance of
each cell surface protein for beta cell homeostasis can of
course be tested in ‘classical’ functional beta cell assays
using cell lines, primary islets and gain-/loss-of-function
mouse models; however, the initial perturbation and pattern
analysis from which the strongest candidates emerge may
also hint at a more precise role of a protein, for example, a
role in insulin granule recycling, establishment of cell po-
larity, fuel utilisation switching or specific nutrient uptake—
all of which will, of course, if they are significantly altered,
affect the fundamental clockwork of the beta cell.
Biomedical applications of the beta cell surface
landscape
What is the promise of a comprehensive beta cell surface
map? The main hope is that it will be the gateway to
targeting and monitoring the function and mass of a cell
type that is scarce in number and otherwise hard to reach.
The proteome will fall into two topological categories of
useful proteins (Fig. 3): permanently beta cell membrane-
associated proteins and shed/secreted proteins. The
constitutive surface proteins may, provided they are beta
cell-specific or -enriched, serve as drug targets and, in
principle, as docking points/antigens for beta cell sorting
and imaging. The advantage of targeting surface proteins is
not only the likely accessibility of the proteins, but also the
fact that very often they are found at the beginning of an
amplifying signalling cascade, so that affecting one protein,
such as a tyrosine kinase receptor, may have large and
pleiotropic cellular effects. The current methods used to sort
genetically unmodified beta cells (i.e. no fluorescent protein
under a beta cell-specific promoter) are based on the differ-
ential autofluorescent properties of these cells compared
with the rest of the islet as a result of different ion or
metabolite contents [98], and unfortunately, yields, viability
and purity are still poor. Imaging techniques, such as posi-
tron emission tomography (PET) and MRI can currently
only reveal beta cells/islets that have previously been chem-
ically treated ex vivo [99] because of the lack of a suitable
antigen and/or antibody that could be coupled to a tracer and
used non-invasively. The shed or secreted proteins may be
used as indicators of beta cell mass, function or internal state
in serum or urine. For example, the cleavage fragment of a
structural component of beta cells will roughly correlate
with the number of beta cells in the body. Such an accurate
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Fig. 3 The three steps to characterising the beta cell surface proteome
for diagnostic and therapeutic purposes. (a) Identification of the sur-
face proteome, (b) analysis of its dynamic regulation, (c) assessment of
the potential use of individual proteins as biomarkers, imaging tools
and drug targets
Diabetologia (2012) 55:1877–1889 1885marker of beta cell mass is desperately needed to assess and
appropriately treat type 1 and type 2 diabetes. At present, the
main indicator is plasma insulin, levels of which can be
maintained after a beta cell loss of up to 80% via functional
compensation by the remaining pool. A stressed beta cell
may secrete endoplasmic reticulum stress proteins or auto-
phagosomal or apoptotic proteins that leak through the
secretory pathway, and so the overall state of the beta cell
could be evaluated. In a more therapy-specific way, the
sheddome could also be used to monitor the effectiveness
of a beta cell-selective protease inhibitor or islet regenera-
tion/transplantation approaches. The challenge here is not
only to find those molecules that are beta cell-enriched or
beta cell-specific, but also those that are feasibly detectable
by ELISA or other clinically compatible diagnostic techni-
ques. Even without clearance by the kidney or other tissues,
it is to be expected that such beta cell-derived proteins will
be found in serum only at picograms per millilitre to low
nanograms per millilitre levels—given that the concentra-
tions of insulin, the most abundant secreted beta cell protein,
lie in the nanogram range and, in comparison, prostate
specific antigen (PSA), a secreted serine protease and mark-
er for prostate cancer, is only present at low nanograms per
millilitre levels even in cancer positive patients, yet is in-
dicative of an organ that is more than 10 times larger than
the entire beta cell pool (an average of 11 g prostate versus
0.8 g beta cells). However, if there is a need there is a way
and, depending on the chosen biomarker, amplification
methods may be at hand: for example, a hypothetical
shed fragment with remaining enzymatic activity may
be exploited to design an activity rather than concentra-
tion–based detection assay. The numerous potential appli-
cations of the beta cell derived surfaceome are thus,
paradoxically, tightly linked not only to the importance
of this cell but much rather precisely to its low abun-
dance and anatomical remoteness.
The promise of a comprehensive beta cell surface map is
a rational approach to targeting and monitoring the function
and mass of a cell type that is scarce in number and
otherwise difficult to access
Concluding remarks
Pancreatic beta cell functionality is crucial for maintaining
glucose homeostasis. Historically, many proteins pivotal to
its insulin secretory capacity and adaptability by mass ex-
pansion proved to be cell surface proteins, making the
plasma membrane an attractive compartment for further
gaining insight into how the beta cell senses and responds
to its environment and for exploring candidates for drug
development or beta cell markers. Also, early perturbing
events at the cell surface could conceivably be involved in
the development of beta cell dysfunction. Thus, qualitative
and quantitative characterisation of the proteome may also
help us understand these processes. With an increasing
number of plasma membrane enrichment strategies fol-
lowed by sensitive mass spectrometry, the dynamic sur-
faceome, sheddome and secretome of the beta cell are on
the verge of being mapped. The challenges will then be
to systematically assess these proteins functionally, and
establish those that are critical members of the functional
beta cell surface landscape and thus harbour therapeutic
potential.
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